Plain-English translation of NCT06310551 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing a new HIV medication called VH4524184 that is designed to be given as a long-acting injection instead of daily pills. Researchers are testing two different formulations of the medication to see which works best and is safest when injected under the skin or into muscle. The goal is to find doses that are well-tolerated and could eventually give people with HIV a simpler treatment option.
Many people with HIV currently take daily pills, which can be difficult to remember and manage. This study is exploring whether a long-acting injectable form of this medication could provide protection from HIV with fewer doses, making treatment easier and potentially improving how well people stick with their therapy.
You likely qualify if…
You likely don't qualify if…
Participants will receive either one injection or multiple injections of the medication under the skin or in a muscle, depending on which study group they join. The study includes regular clinic visits where researchers will check your health, take blood samples, and monitor how your body handles the medication. You'll be carefully watched for any side effects, and the whole process helps determine if this medication is safe enough to test in people with HIV.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States